Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants

Treatment and secondary prophylaxis of venous thromboembolism with direct oral anticoagulants in patients with severe hereditary thrombophilia

“…In these cases, we used a long term therapy for the elevated thrombotic risk without a dose-reduction as suggested by registration studies, and no bleeding episodes nor thrombotic recurrences were observed. As described in a recent review, 8 our small setting suggests the efficacy and safety of therapy with anti-Xa (rivaroxaban and apixaban) in the treatment and secondary prophylaxis of VTE in patients with SHT. Further more extensive multicentric studies are needed to obtain statistical significance and guidelines recommendation.…”

“…7 A recent review supports DOAC use for congenital thrombophilia, especially in the high-risk subgroups, and shows how the identification of the exact type of SHT in these studies would help assess the treatment selection. 8…”

Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia

“…We appreciated reading the review article "Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants", published in Thrombosis Research [1]. In order to implement the data about direct oral anticoagulants (DOACs) efficacy and safety in patients affected by congenital thrombophilia, we would like to inform that we published our casuistic of 45 patients (33 previously treated with vitamin K antagonists and 12 with DOACs frontline) [2].…”